Skip to content

it is a study involving vitiligo patients, which will be treated by two separate topical medication followed by procedure with microneedling and NBUVB therapy which will result in darkening of vitiligo patches

a comparative study of the efficacy of the topical triamcinolone acetonide versus topical latanoprost in combination with microneedling and narrowband ultraviolet B phototherapy in the treatment of vitiligo - NIL

Status
Recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/04/065773
Enrollment
21
Registered
2024-04-16
Start date
Unknown
Completion date
Unknown
Last updated
2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: INJECTION TRIAMCINOLONE ACETONIDE: topical application of injection Triamcinolone acetonide available in solution of 10mg/ml following microneedling every 2 weeks for 3 months and nbuvb

Sponsors

mgm medical college and hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: A patient who voluntarily agreed and given consent to participate in the study. A patient who has two or more non segmental, stable vitiligo lesions with similar degree of progression measuring 5cm2 or more present over the face, trunk or limbs. All patients with vitiligo presenting to MGM medical college and hospital.

Exclusion criteria

Exclusion criteria: Local disease such as folliculitis. Patient on anticoagulants and blood thinners Keloidal tendencies HIV, Hepatitis B or C, or otherwise immunocompromised patient. Unrealistic expectations of patients

Design outcomes

Primary

MeasureTime frame
Repigmentation of vitiligo patches will be assessed.Timepoint: patient will be assessed photographically first before intervention and next after 3 months at the end of intervention

Secondary

MeasureTime frame
global assessment of repigmentation of vitiligo patches will be done by patientsTimepoint: after completion of intervention i.e 3 months

Countries

India

Contacts

Public ContactAniruddha gulanikar

Mahatma Gandhi missions institute of health sciences

agulanikar@hotmail.com9822377963

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026